Cargando…
Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The International AIDS Society
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112863/ http://dx.doi.org/10.1186/1758-2652-13-S4-O48 |
| _version_ | 1782205834600644608 |
|---|---|
| author | Cohen, C Molina, JM Cahn, P Clotet, B Fourie, J Grinsztejn, B Hao, W Johnson, M Supparatpinyo, K Crauwels, HM Rimsky, L Vanveggel, S Williams, P Boven, K |
| author_facet | Cohen, C Molina, JM Cahn, P Clotet, B Fourie, J Grinsztejn, B Hao, W Johnson, M Supparatpinyo, K Crauwels, HM Rimsky, L Vanveggel, S Williams, P Boven, K |
| author_sort | Cohen, C |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3112863 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | The International AIDS Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-31128632011-06-13 Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients Cohen, C Molina, JM Cahn, P Clotet, B Fourie, J Grinsztejn, B Hao, W Johnson, M Supparatpinyo, K Crauwels, HM Rimsky, L Vanveggel, S Williams, P Boven, K J Int AIDS Soc Oral Presentation The International AIDS Society 2010-11-08 /pmc/articles/PMC3112863/ http://dx.doi.org/10.1186/1758-2652-13-S4-O48 Text en Copyright ©2010 Cohen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Oral Presentation Cohen, C Molina, JM Cahn, P Clotet, B Fourie, J Grinsztejn, B Hao, W Johnson, M Supparatpinyo, K Crauwels, HM Rimsky, L Vanveggel, S Williams, P Boven, K Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients |
| title | Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients |
| title_full | Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients |
| title_fullStr | Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients |
| title_full_unstemmed | Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients |
| title_short | Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients |
| title_sort | pooled week 48 safety and efficacy results from the echo and thrive phase iii trials comparing tmc278 vs efv in treatment-naïve, hiv-1-infected patients |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112863/ http://dx.doi.org/10.1186/1758-2652-13-S4-O48 |
| work_keys_str_mv | AT cohenc pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT molinajm pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT cahnp pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT clotetb pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT fouriej pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT grinsztejnb pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT haow pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT johnsonm pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT supparatpinyok pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT crauwelshm pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT rimskyl pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT vanveggels pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT williamsp pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients AT bovenk pooledweek48safetyandefficacyresultsfromtheechoandthrivephaseiiitrialscomparingtmc278vsefvintreatmentnaivehiv1infectedpatients |